No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Oncolytics Biotech Inc: INTERIM MDA EN
Oncolytics Biotech Inc: INTERIM FINANCIAL STATEMENTSREPORT EN
Oncolytics Brief: Notes American Society of Clinical Oncology (ASCO) GI Symposium Data "Underscores Pelareorep's Clinical Benefit In Anal and Pancreatic Cancers"
Oncolytics Brief: Says Poster On Pelareorep's Stimulation of Adaptive and Innate Immunity To Be Shared at ASCO Annual Meeting
Oncolytics Biotech Q1 EPS $(0.06) Beats $(0.09) Estimate
Oncolytics Brief: Says Basic and Diluted Loss Per Share Was $0.08 In Q1 2025